CYBN (Cybin) Enterprise Value-to-Revenue Multiple

Cybin Inc. (CYBN) - corporate logo

Cybin Inc. is focusing on completing final clinical trials and securing patent protection for its innovative depression therapy. The process is being accelerated through bioinformatic modeling and automated molecular screening. Since success depends on medicine rather than economics, the enterprise value-to-revenue dynamic serves as an objective indicator, where the parameter has stabilized at 0.00.

Cybin Inc (CYBN) - EV/Sales Multiple from 11/23/2025 to 01/05/2026

Financial and market metric breakdowns for Cybin (CYBN)

- market value and analyst target forecast:
- business market valuation indicators:
Fundamental company valuation:CYBN (Cybin Corp)
Finished products of cybin.com

Investors assess fundamental capital risks through the ratio of business value to operating income. For Cybin Inc. (CYBN), the completion timelines for psychedelic clinical trials are critical, as commercial revenue is currently nonexistent. The EV/Sales metric combines market capitalization and net debt, benchmarking them against sales volume. The stability of this chart reflects market expectations for future products, while the current smooth trajectory signals that speculative hopes are fully priced in.